Floatz logo

27 assets in Heart Failure

Therapeutic assets addressing Heart Failure, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Empagliflozin
Heart Failure
Jacob MollerP4BB (66)
Finerenone
Heart Failure
Hospital de Messejana Dr. Carlos Alberto Studart GomesP4BB (65)
Semaglutide
Heart Failure
University Medical Centre LjubljanaP2/3BB (64)
Acalabrutinib
Heart Failure
AstraZenecaP4B (62)
Dapagliflozin
Heart Failure
University Medical Centre LjubljanaP3B (62)
Sacubitril Valsartan
Heart Failure
Silesian Centre for Heart DiseasesP4B (62)
Spironolactone
Heart Failure
Hospital de Messejana Dr. Carlos Alberto Studart GomesP4B (62)
Maridebart Cafraglutide
Heart Failure
AmgenP3B (60)
Apixaban
Heart Failure
Columbia UniversityP3B (57)
nnc0487-0111
Heart Failure
Novo Nordisk A/SP3B (57)
Warfarin
Heart Failure
Columbia UniversityP3B (57)
AIR
Heart Failure
Turku University HospitalP2CCC (53)
Mazdutide
Heart Failure
Innovent Biologics (Suzhou) Co. Ltd.P2CCC (53)
Oxygen
Heart Failure
Turku University HospitalP2CCC (53)
Pertuzumab
Heart Failure
Population Health Research InstituteP2CCC (53)
Trastuzumab
Heart Failure
Population Health Research InstituteP2CCC (53)
Trastuzumab Emtansine
Heart Failure
Population Health Research InstituteP2CCC (53)
Vericiguat
Heart Failure
Memorial Sloan Kettering Cancer CenterP2CCC (53)
XENON
Heart Failure
Turku University HospitalP2CCC (53)
Pyruvate
Heart Failure
National Heart Centre SingaporeP2CCC (49)
Human Relaxin 1
Heart Failure
Deeptankar DeMazumderP1/2CC (45)
Thrv-1268
Heart Failure
Thryv Therapeutics, Inc.P1CC (44)
ACETIC
Heart Failure
Ottawa Heart Institute Research CorporationN/AD (30)
Angiotensin 1-7
Heart Failure
University of ArizonaP1/2NR ()
Hrs-7535
Heart Failure
Shandong Suncadia Medicine Co., Ltd.P2NR ()
Nitroglycerin Tablets
Heart Failure
Copenhagen University Hospital, HvidovreP4NR ()